WindMIL Therapeutics Expands Leadership TeamHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)WindMIL Therapeutics Expands Leadership TeamGlobeNewswireJanuary 7, 2020ReblogShareTweetShareCompany Appoints Karen LaRochelle as Senior Vice President, Corporate & Business Development and Promotes Patrick Dougherty to Senior Vice President, Strategy, Planning & OperationsBALTIMORE and PHILADELPHIA, Jan. 07, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, today announced the expansion of its leadership team with the appointment of Karen LaRochelle as Senior Vice President, Corporate & Business Development and the promotion of Patrick Dougherty to Senior Vice President, Strategy, Planning & Operations.“During the fourth quarter of 2019, we significantly advanced our development of MILs as we dosed the first patient in our Phase 2 non-small cell lung cancer study and reported additional data on gene-modified MILs (CAR-MILs),” said Don Hayden, chairman and chief executive officer of WindMIL. “The addition of Karen and promotion of Patrick allow us to further expand and accelerate our efforts as we continue to advance our understanding of the benefits that this novel class of autologous cell therapies for cancer immunotherapy might provide to cancer patients.”Ms. LaRochelle will be responsible for facilitating business growth, defining partnering strategy, spearheading collaborations and evaluating new corporate and business development opportunities. She joins WindMIL with more than 25 years of industry experience focused on strategy and collaborations for pharmaceutical and biotechnology companies in the United States, Europe and China, including strategic collaborations, mergers & acquisitions and licensing. Previously, Ms. LaRochelle was Chief Business Officer of PsiOxus Therapeutics and she also provided multiple biotechnology companies with business development and collaboration consulting services. Prior to that, Ms. LaRochelle spent nearly 20 years with Bristol-Myers Squibb, most recently as Global Head of Negotiations and Head of Business Development in China. She received her MBA from Columbia University and BS in Industrial Engineering from Lehigh University.Mr. Dougherty has been a key member of the WindMIL leadership team for two years. He will be adding corporate strategy and early commercial planning to the areas he currently leads for the company, which include business planning and operations, human resources, communications, information technology and facilities. Prior to joining WindMIL, Mr. Dougherty held a series of leadership roles at GlaxoSmithKline (GSK) including Chief of Staff to the SVP R&D Pipeline for Pharmaceuticals R&D. Prior to GSK, Mr. Dougherty was an engagement manager for L.E.K. Consulting and he has also held various roles in business and corporate development at Endo Pharmaceuticals, Laboratorios Bagó and the Center for Technology Transfer at the University of Pennsylvania. He holds a BS in Chemistry from Villanova University, an MSc in Technology Management from the University of Manchester (UK) and an MBA from the Wharton School, University of Pennsylvania.About WindMIL TherapeuticsWindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow infiltrating lymphocytes (MILs™) for cancer immunotherapy. As the leader in cellular therapeutics emanating from bone marrow, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients. The company’s proprietary process to activate and expand these cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxic potential and long persistence. For more information, please visit: https://windmiltx.com.  WindMIL Therapeutics Media Contact:Gina Cestari6 Degrees(917) 797-7904gcestari@6degreespr.comPhotos accompanying this announcement are available at:https://www.globenewswire.com/NewsRoom/AttachmentNg/4157998b-3efb-47f5-87d5-ef02ba512337https://www.globenewswire.com/NewsRoom/AttachmentNg/2aeab1b9-7017-48d1-8898-37bd87e583eeReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextDiscovery taps Hulu’s Lisa Holme to head direct-to-consumer effortsAmerican City Business JournalsFormer Enterprise Bank CEO Peter Benoist diesAmerican City Business JournalsSiteOne Landscape Supply adds Lowe's veteran to its C-SuiteAmerican City Business JournalsBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceQ4 e-commerce sales are what's 'saving Walmart': AnalystYahoo Finance Video